|Study Description:||The goal of this clinical research study is to compare how two different drugs, |
decitabine and azacitidine, when given on a shorter than standard dosing
schedule can help to control MDS. The safety of the drugs will also be studied.
Decitabine is designed to damage the DNA (the genetic material) of cells, which
may cause cancer cells to die.
Azacitidine is designed to block certain proteins in cancer cells whose job is
to stop the function of the tumor-fighting proteins. By blocking the "bad"
proteins, the tumor-fighting genes may be able to work better. This could
cause the cancer cells to die.